How Psychedelic Biotech Is Reshaping Mental Health | Eric So - CEO, Helus Pharma

Psychedelic medicine is no longer fringe science - it’s now part of White House policy discussions, FDA fast-track programs, and a rapidly emerging neuropsychiatric industry. But can these therapies truly become scalable standards of care?

Eric So is Co-Founder and Executive Chairman of Helus Pharma ( https://www.helus.com/ ), a company focused on developing next-generation serotonergic therapies for mental illness and advancing the broader field of psychedelic-assisted psychiatry. With a multidisciplinary background spanning science, law, finance, and entrepreneurship, Eric has spent his career building and scaling public and private companies across emerging sectors.

Before launching Helus Pharma in 2019, Eric was involved with a number of high-growth ventures, including leadership roles at Globalive Technology and Therapix Biosciences Ltd., where he gained firsthand experience navigating the intersection of biotechnology innovation, regulation, and capital markets. He earned a Bachelor of Science in Cell Biology and Anatomy from McGill University before obtaining his law degree from University of Windsor.

Today, Eric is helping shape conversations around how psychedelic medicines move from promising experimental therapies into scalable, evidence-based standards of care. His work comes at a pivotal moment for the field, as regulators, policymakers, clinicians, and industry leaders debate how to responsibly accelerate treatments for conditions such as depression, PTSD, addiction, and treatment-resistant mental illness - particularly for veterans and underserved patient populations. 

Following recent recognition of Helus Pharma in a White House discussion around psychedelic drug development and policy, Eric joins us to discuss the future of psychedelic medicine, the evolving regulatory landscape, and what it will take to translate scientific promise into real-world psychiatric care.

#Psychedelics #MentalHealth #PsychedelicMedicine #Psychiatry #Neuroscience #Biotech #HelusPharma #EricSo #DepressionTreatment #PTSD #VeteransMentalHealth #PsychedelicTherapy #Neuroplasticity #PrecisionPsychiatry #FDA #DrugDevelopment #Ibogaine #Psilocybin #SerotonergicAgonists #FutureOfMedicine #Longevity #BrainHealth #Biotechnology #MentalHealthInnovation #HealthcareInnovation